These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 8790908

  • 21. Increased urokinase and consumption of α2 -antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay.
    Longstaff C, Locke M.
    J Thromb Haemost; 2019 Jan; 17(1):195-205. PubMed ID: 30451372
    [Abstract] [Full Text] [Related]

  • 22. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
    Rijken DC, Abdul S, Malfliet JJ, Leebeek FW, Uitte de Willige S.
    J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
    Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH.
    Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
    [Abstract] [Full Text] [Related]

  • 25. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor.
    Sakata Y, Eguchi Y, Mimuro J, Matsuda M, Sumi Y.
    Blood; 1989 Dec; 74(8):2692-7. PubMed ID: 2510836
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR, Gardell SJ.
    Thromb Haemost; 1992 Aug 03; 68(2):165-9. PubMed ID: 1412162
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
    Collen D, Van Hoef B, Schlott B, Hartmann M, Gührs KH, Lijnen HR.
    Eur J Biochem; 1993 Aug 15; 216(1):307-14. PubMed ID: 7689966
    [Abstract] [Full Text] [Related]

  • 32. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
    Kluft C, Nieuwenhuis HK, Rijken DC, Groeneveld E, Wijngaards G, van Berkel W, Dooijewaard G, Sixma JJ.
    J Clin Invest; 1987 Nov 15; 80(5):1391-400. PubMed ID: 2445779
    [Abstract] [Full Text] [Related]

  • 33. Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation.
    Henderson SJ, Stafford AR, Leslie BA, Kim PY, Vaezzadeh N, Ni R, Fredenburgh JC, Weitz JI.
    Thromb Haemost; 2015 Jun 15; 113(6):1278-88. PubMed ID: 25789495
    [Abstract] [Full Text] [Related]

  • 34. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A, Markart P, Kalinowski M, Ruppert C, Grimminger F, Seeger W.
    Am J Respir Cell Mol Biol; 1999 Dec 15; 21(6):738-45. PubMed ID: 10572071
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Plasminogen assay by means of the lysis time method.
    Berg W, Korsan-Bengtsen K, Ygge J.
    Thromb Diath Haemorrh; 1965 Sep 01; 14(1-2):127-44. PubMed ID: 16955971
    [Abstract] [Full Text] [Related]

  • 37. On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin.
    Lijnen HR, Van Hoef B, Matsuo O, Collen D.
    Biochim Biophys Acta; 1992 Jan 09; 1118(2):144-8. PubMed ID: 1730031
    [Abstract] [Full Text] [Related]

  • 38. Analysis of plasminogen activation by the plasmin-staphylokinase complex in plasma of alpha2-antiplasmin-deficient mice.
    Okada K, Ueshima S, Tanaka M, Fukao H, Matsuo O.
    Blood Coagul Fibrinolysis; 2000 Oct 09; 11(7):645-55. PubMed ID: 11085285
    [Abstract] [Full Text] [Related]

  • 39. Inactivation of purified human alpha 2-antiplasmin and purified human C1 inhibitor by synthetic fibrinolytic agents.
    Miles LA, Burnier JP, Verlander MS, Goodman M, Kleiss AJ, Griffin JH.
    Blood; 1981 Jun 09; 57(6):1015-24. PubMed ID: 6452920
    [Abstract] [Full Text] [Related]

  • 40. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F, Hasegawa N, Asano K, Sayama K, Fujita H, Urano T, Aoki T, Ishizaka A, Kanazawa M, Kawashiro T.
    Kokyu To Junkan; 1992 Jul 09; 40(7):685-90. PubMed ID: 1387724
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.